Humana (NYSE:HUM) Price Target Lowered to $381.00 at Jefferies Financial Group

Humana (NYSE:HUM) had its price objective cut by equities researchers at Jefferies Financial Group from $411.00 to $381.00 in a report issued on Monday, Benzinga reports. The firm presently has a “buy” rating on the insurance provider’s stock. Jefferies Financial Group’s price target would suggest a potential upside of 16.22% from the company’s previous close.

Several other analysts have also issued reports on the stock. Truist Financial reiterated a “hold” rating and set a $550.00 price target on shares of Humana in a research report on Friday, January 19th. Mizuho lowered their price target on Humana from $550.00 to $400.00 and set a “buy” rating for the company in a report on Friday, January 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $391.00 price objective on shares of Humana in a research note on Wednesday, April 10th. Wells Fargo & Company decreased their target price on Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research report on Monday, April 8th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Humana from a “buy” rating to a “hold” rating and dropped their target price for the stock from $595.00 to $360.00 in a report on Thursday, January 25th. Eleven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $454.63.

Humana Price Performance

Shares of NYSE HUM opened at $327.84 on Monday. The business has a fifty day moving average price of $329.86 and a two-hundred day moving average price of $398.38. The stock has a market capitalization of $39.55 billion, a PE ratio of 16.54, a P/E/G ratio of 1.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59. Humana has a fifty-two week low of $299.23 and a fifty-two week high of $541.21.

Humana (NYSE:HUM) last issued its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). The company had revenue of $26.46 billion during the quarter, compared to the consensus estimate of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. The firm’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.62 EPS. As a group, equities analysts predict that Humana will post 16.06 earnings per share for the current fiscal year.

Insider Transactions at Humana

In related news, Director Jorge S. Mesquita bought 545 shares of Humana stock in a transaction that occurred on Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the acquisition, the director now directly owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.29% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Humana

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Dorsey & Whitney Trust CO LLC raised its position in shares of Humana by 2.6% in the 3rd quarter. Dorsey & Whitney Trust CO LLC now owns 817 shares of the insurance provider’s stock worth $397,000 after acquiring an additional 21 shares in the last quarter. UMB Bank n.a. increased its holdings in Humana by 2.8% in the third quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock worth $392,000 after purchasing an additional 22 shares in the last quarter. First Financial Corp IN lifted its stake in Humana by 7.2% in the fourth quarter. First Financial Corp IN now owns 343 shares of the insurance provider’s stock valued at $157,000 after buying an additional 23 shares during the period. PDS Planning Inc boosted its holdings in shares of Humana by 4.1% during the 3rd quarter. PDS Planning Inc now owns 609 shares of the insurance provider’s stock worth $296,000 after buying an additional 24 shares in the last quarter. Finally, First Trust Direct Indexing L.P. grew its position in shares of Humana by 0.8% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 2,926 shares of the insurance provider’s stock worth $1,424,000 after buying an additional 24 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.